SSAC: iShares MSCI ACWI UCITS ETF (Acc) returns, drawdowns and risk
iShares MSCI ACWI UCITS ETF (Acc). Global equity funds: developed markets only (MSCI World) or developed plus emerging (FTSE All-World, MSCI ACWI). Also listed as IUSQ on Xetra.
SSAC · Borsa Italiana · EURCategory: World and all-world ETFs
Figures for SSAC are being calculated and will appear shortly.
Use SSAC in a free tool
- Monthly investing in SSACDCA calculator with real returns
- SSAC correlation matrixAgainst VWCE and similar funds
- SSAC rolling returnsBest and worst 1–15 year periods
- SSAC drawdowns and recoveriesHow long each fall took to recover
- Backtest SSAC in a portfolioAdd up to 4 more funds
- Stress test a portfolioYour own scenarios, holding by holding
- Portfolio analytics software comparedFeatures and prices side by side
- SSAC in italianoRendimento a 10 anni e PAC
Other World and all-world ETFs
- All World and all-world ETFsReturns and risk side by side
- VWCE — Vanguard FTSE All-World UCITS ETF (Acc)CAGR +12.7%
- SWDA — iShares Core MSCI World UCITS ETF (Acc)CAGR +12.4%
- VT — Vanguard Total World Stock ETFCAGR +14.6%
- ACWI — iShares MSCI ACWI ETFCAGR +8.5%
- VWRL — Vanguard FTSE All-World UCITS ETF (Dist)CAGR +11.7%
- XDWD — Xtrackers MSCI World UCITS ETF 1CCAGR +12.6%
- IUSN — iShares MSCI World Small Cap UCITS ETFCAGR +9.4%
How the figures are calculated
Total return in the fund’s trading currency, from end-of-day prices with dividends reinvested on the ex-date. The fund’s own ongoing charges are already reflected in its price; trading costs, taxes and currency conversion are not included. Past returns do not predict future returns.
Sharpe ratio uses the return of short-term government bills in the same currency as the risk-free rate. Holding periods, the monthly-investing example and the comparison with other funds use month-end values; drawdowns and volatility use daily closes.
Source: MarketStack end-of-day prices, total return with dividends reinvested. Figures are historical and descriptive; they are not forecasts and not investment advice. MEDGE Capital does not recommend buying or selling any instrument. Risk disclaimer.